Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE